Filtered By:
Nutrition: Sodium
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 1017 results found since Jan 2013.
Neurosurgery Morbidity and Mortality: A Prospective Surgical and Medical Analysis
CONCLUSION: The mortality and morbidity analysis provided valuable neurosurgical information that may influence future treatment management and corrective recommendations. Indication and judgment errors were significantly associated with mortality. In our study, the patients' comorbidities were not significant for mortality or increased length of stay.PMID:36941096
Source: Puerto Rico Health Sciences Journal - March 20, 2023 Category: International Medicine & Public Health Authors: Orlando De Jesus Jos é I Sandoval-Consuegra Aixa De Jes ús-Espinosa Ricardo J Fern ández-de Thomas C ésar M Carballo-Cuello Source Type: research
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Patients with type 2 diabetes are at increased risk for cardiovascular diseases. Sodium-glucose transport 2 inhibitors (SGLT2i) have been shown to enhance cardiovascular health since their debut as a second-li...
Source: Cardiovascular Diabetology - March 13, 2023 Category: Cardiology Authors: Pei-Chien Tsai, Wei-Jung Chuang, Albert Min-Shan Ko, Jui-Shuan Chen, Cheng-Hsun Chiu, Chun-Han Chen and Yung-Hsin Yeh Tags: Research Source Type: research
Molecules, Vol. 28, Pages 2598: Gastrodin and Gastrodigenin Improve Energy Metabolism Disorders and Mitochondrial Dysfunction to Antagonize Vascular Dementia
This study explored the effects of Gas and HBA on cognitive dysfunction in VD and their possible molecular mechanisms. The VD model was established by bilateral common carotid artery ligation (2-vessel occlusion, 2-VO) combined with an intraperitoneal injection of sodium nitroprusside solution. One week after modeling, Gas (25 and 50 mg/kg, i.g.) and HBA (25 and 50 mg/kg, i.g.) were administered orally for four weeks, and the efficacy was evaluated. A Morris water maze test and passive avoidance test were used to observe their cognitive function, and H&E staining and Nissl staining were used to observe the neur...
Source: Molecules - March 13, 2023 Category: Chemistry Authors: Sha Wu Rong Huang Ruiqin Zhang Chuang Xiao Lueli Wang Min Luo Na Song Jie Zhang Fang Yang Xuan Liu Weimin Yang Tags: Article Source Type: research
Long ‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
ConclusionsIn patients with acute decompensated HFpEF, over 5 years of follow-up, nearly of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both ou tcomes.
Source: ESC Heart Failure - March 11, 2023 Category: Cardiology Authors: Angiza Shahim,
Marion Hourqueig,
Lars H. Lund,
Gianluigi Savarese,
Emmanuel Oger,
Ashwin Venkateshvaran,
Lina Benson,
Jean ‐Claude Daubert,
Cecilia Linde,
Erwan Donal,
Camilla Hage Tags: Original Article Source Type: research
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
Cardiol Res. 2023 Feb;14(1):12-21. doi: 10.14740/cr1459. Epub 2023 Feb 25.ABSTRACTBeyond improving hemoglobin A1c (HbA1c) in adults with type 2 diabetes, glucagon-like peptide 1 receptor agonists (GLP-1RA) have been approved for reducing risk of major adverse cardiovascular events (MACE) with established cardiovascular disease (CVD) or multiple CV risk factors. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) also reduced the risk for the primary composite CV outcome in patients with type 2 diabetes at high risk for CV events. In the American Diabetes Association (ADA) and European Association of Study in Diabetes (EASD)...
Source: Atherosclerosis - March 10, 2023 Category: Cardiology Authors: Hidekatsu Yanai Hiroki Adachi Mariko Hakoshima Hisayuki Katsuyama Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes
J Clin Endocrinol Metab. 2023 Feb 28:dgad113. doi: 10.1210/clinem/dgad113. Online ahead of print.ABSTRACTBACKGROUND: SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3P MACE), predominantly by reducing cardiovascular death. However reduction of the individual components, myocardial infarction (MI) or stroke (fatal and non-fatal) events have not been well explored.METHODS: In this meta-analysis, we included data avail...
Source: The Journal of Clinical Endocrinology and Metabolism - March 1, 2023 Category: Endocrinology Authors: Pradip Mukhopadhyay Debmalya Sanyal Purushottam Chatterjee Kaushik Pandit Sujoy Ghosh Source Type: research
